538 related articles for article (PubMed ID: 15519027)
1. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
[TBL] [Abstract][Full Text] [Related]
2. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
Barefield D; Kumar M; de Tombe PP; Sadayappan S
Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
[TBL] [Abstract][Full Text] [Related]
3. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
Ho CY; Lakdawala NK; Cirino AL; Lipshultz SE; Sparks E; Abbasi SA; Kwong RY; Antman EM; Semsarian C; González A; López B; Diez J; Orav EJ; Colan SD; Seidman CE
JACC Heart Fail; 2015 Feb; 3(2):180-8. PubMed ID: 25543971
[TBL] [Abstract][Full Text] [Related]
4. Hypertrophic cardiomyopathy mutations in
Toepfer CN; Wakimoto H; Garfinkel AC; McDonough B; Liao D; Jiang J; Tai AC; Gorham JM; Lunde IG; Lun M; Lynch TL; McNamara JW; Sadayappan S; Redwood CS; Watkins HC; Seidman JG; Seidman CE
Sci Transl Med; 2019 Jan; 11(476):. PubMed ID: 30674652
[TBL] [Abstract][Full Text] [Related]
5. Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes.
Field E; Norrish G; Acquaah V; Dady K; Cicerchia MN; Ochoa JP; Syrris P; McLeod K; McGowan R; Fell H; Lopes LR; Cervi E; Kaski JPP
J Med Genet; 2022 Aug; 59(8):768-775. PubMed ID: 34400558
[TBL] [Abstract][Full Text] [Related]
6. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
[TBL] [Abstract][Full Text] [Related]
7. Whole gene sequencing identifies deep-intronic variants with potential functional impact in patients with hypertrophic cardiomyopathy.
Mendes de Almeida R; Tavares J; Martins S; Carvalho T; Enguita FJ; Brito D; Carmo-Fonseca M; Lopes LR
PLoS One; 2017; 12(8):e0182946. PubMed ID: 28797094
[TBL] [Abstract][Full Text] [Related]
8. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.
Suay-Corredera C; Pricolo MR; Herrero-Galán E; Velázquez-Carreras D; Sánchez-Ortiz D; García-Giustiniani D; Delgado J; Galano-Frutos JJ; García-Cebollada H; Vilches S; Domínguez F; Molina MS; Barriales-Villa R; Frisso G; Sancho J; Serrano L; García-Pavía P; Monserrat L; Alegre-Cebollada J
J Biol Chem; 2021 Jul; 297(1):100854. PubMed ID: 34097875
[TBL] [Abstract][Full Text] [Related]
9. Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy.
Mademont-Soler I; Mates J; Yotti R; Espinosa MA; Pérez-Serra A; Fernandez-Avila AI; Coll M; Méndez I; Iglesias A; Del Olmo B; Riuró H; Cuenca S; Allegue C; Campuzano O; Picó F; Ferrer-Costa C; Álvarez P; Castillo S; Garcia-Pavia P; Gonzalez-Lopez E; Padron-Barthe L; Díaz de Bustamante A; Darnaude MT; González-Hevia JI; Brugada J; Fernandez-Aviles F; Brugada R
PLoS One; 2017; 12(8):e0181465. PubMed ID: 28771489
[TBL] [Abstract][Full Text] [Related]
10. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
Topriceanu CC; Pereira AC; Moon JC; Captur G; Ho CY
Circulation; 2024 Jan; 149(2):107-123. PubMed ID: 37929589
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic spectrum of the first Belgian
Boen HM; Alaerts M; Van Laer L; Saenen JB; Goovaerts I; Bastianen J; Koopman P; Vanduynhoven P; De Vuyst E; Rosseel M; Heidbuchel H; Van Craenenbroeck EM; Loeys B
Front Genet; 2024; 15():1392527. PubMed ID: 38836037
[TBL] [Abstract][Full Text] [Related]
12. Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.
Ribeiro M; Jager J; Furtado M; Carvalho T; Cabral JMS; Brito D; Carmo-Fonseca M; Martins S; da Rocha ST
Hum Cell; 2024 Jul; 37(4):1205-1214. PubMed ID: 38762696
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and phenotypes associated with ALPK3 null variants in a large French multicentric cohort: Confirming its involvement in hypertrophic cardiomyopathy.
Ader F; Jedraszak G; Janin A; Billon C; Buisson NR; Bloch A; Bensalah M; De Sandre-Giovannoli A; Goudal A; Marsili L; Cazeneuve C; Charron P; Millat G; Richard P;
Clin Genet; 2024 Jun; 105(6):676-682. PubMed ID: 38356193
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine validation: identifying the
Ontiveros ES; Ueda Y; Harris SP; Stern JA;
J Feline Med Surg; 2019 Dec; 21(12):1086-1093. PubMed ID: 30558461
[TBL] [Abstract][Full Text] [Related]
15. Integrating Clinical Phenotype With Multiomics Analyses of Human Cardiac Tissue Unveils Divergent Metabolic Remodeling in Genotype-Positive and Genotype-Negative Patients With Hypertrophic Cardiomyopathy.
Nollet EE; Schuldt M; Sequeira V; Binek A; Pham TV; Schoonvelde SAC; Jansen M; Schomakers BV; van Weeghel M; Vaz FM; Houtkooper RH; Van Eyk JE; Jimenez CR; Michels M; Bedi KC; Margulies KB; Dos Remedios CG; Kuster DWD; van der Velden J
Circ Genom Precis Med; 2024 Jun; 17(3):e004369. PubMed ID: 38853772
[TBL] [Abstract][Full Text] [Related]
16. Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers.
Jansen M; Schmidt AF; Jans JJM; Christiaans I; van der Crabben SN; Hoedemaekers YM; Dooijes D; Jongbloed JDH; Boven LG; Lekanne Deprez RH; Wilde AAM; van der Velden J; de Boer RA; van Tintelen JP; Asselbergs FW; Baas AF
J Cardiovasc Transl Res; 2023 Dec; 16(6):1267-1275. PubMed ID: 37278928
[TBL] [Abstract][Full Text] [Related]
17. MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.
Kuster DW; Sadayappan S
Pflugers Arch; 2014 Feb; 466(2):207-13. PubMed ID: 24327208
[TBL] [Abstract][Full Text] [Related]
18. Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C.
Stern JA; Rivas VN; Kaplan JL; Ueda Y; Oldach MS; Ontiveros ES; Kooiker KB; van Dijk SJ; Harris SP
Sci Rep; 2023 Jun; 13(1):10319. PubMed ID: 37365215
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy.
Daw EW; Chen SN; Czernuszewicz G; Lombardi R; Lu Y; Ma J; Roberts R; Shete S; Marian AJ
Hum Mol Genet; 2007 Oct; 16(20):2463-71. PubMed ID: 17652099
[TBL] [Abstract][Full Text] [Related]
20. Genetic considerations in hypertrophic cardiomyopathy.
Ho CY
Prog Cardiovasc Dis; 2012; 54(6):456-60. PubMed ID: 22687586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
